Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Individualized Tumor Neoantigen Peptide Vaccine in Combination with Unusual Immune Stimulating Radiotherapy in Refractory Solid Tumors (iNATURE) - a Phase II Randomized and Crossover Study

NCT06314087 is registered in ClinicalTrials.gov with The University of Hong Kong-Shenzhen Hospital as lead sponsor.

NCT NCT06314087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06314087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Individualized Tumor Neoantigen Peptide Vaccine in Combination with Unusual Immune Stimulating Radiotherapy in Refractory Solid Tumors (iNATURE) - a Phase II Randomized and Crossover Study
Lead sponsor
The University of Hong Kong-Shenzhen Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
January 31, 2024
Completion date
August 31, 2026
Enrollment
154 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced tumors